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a. (E)-4-((4-bromophenyl)diazenyl)-2,5-dimethoxyaniline (2a)
According to the general procedure A, and using 4-bromoaniline 1a (1.00 g, 5.81 mmol) as starting material, after purification by flash column chromatography (PE/EtOAc +0.5% TEA: 7/3 to 5/5), the diazenyl aniline compound 2a was isolated as a red solid (1.10 g, 57%). R f = 0.43 (PE/EtOAc: 6/4); Mp = 125 °C; 1 H NMR (400 MHz, CDCl 3 ) δ: 7.70 (d, J = 8 Hz, 2H), 7.57 (d, J =8 Hz, 2H), 7. 38 (s, 1H), 6.37 (s, 1H), 4.39 (brs, 2H), 3.97 (s, 3H), 3.89 (s, 3H); 13 C NMR (101 MHz, CDCl 3 ) δ: 55. 9, 57.0, 98.2, 98.3, 123.1, 123.9, 127.6, 132.1, 142.0, 142.6, 152.4, 154.9 ; IR (ATR, neat) ν = 3479, 3369, 2924, 1604, 1505, 1290 
b. (E)-4-((4-chlorophenyl)diazenyl)-2,5-dimethoxyaniline (2b)
Cl N N
NH 2 MeO OMe
According to the general procedure A and starting from 4-chloroaniline 1b (250 mg, 1.96 mmol), after purification by flash column chromatography (PE/EtOAc: 8/2 to 6/4), the diazenyl aniline product 2b was isolated as a red solid (150 mg, 26%). R f = 0.23 (PE/EtOAc: 8/2); Mp = 124 °C.; 1 H NMR (400 MHz, CDCl 3 ) δ: 7.77 (d, J = 8 Hz, 2H), 7.42 (d, J = 8 Hz, 2H), 7.39 (s, 1H), 6.37 (s, 1H), 4.41 (brs, 2H), 3.96 (s, 3H), 3.89 (s, 3H); 13 C NMR (101 MHz, CDCl 3 ) δ: 55. 9, 57.0, 98.2, 98.3, 123.6, 129.1, 133.6, 134.8, 141.9, 142.6, 152.0, 154.8; IR (ATR, neat) 
c. (E)-2,5-dimethoxy-4-((4-methoxyphenyl)diazenyl)aniline (2c)
MeO N N NH 2 MeO
OMe According to the general procedure A and starting from p-anisidine 1c (163 mg, 1.24 mmol), after purification by flash column chromatography (PE/EtOAc: 7/3), the diazenyl aniline product 2c was isolated as a red-orange solid (300 mg, 84%). R f = 0.81 (PE/EtOAc: 4/6); Mp = 164 °C; 1 H NMR (400 MHz, CDCl 3 ) δ: 7.84 (d, J = 8.0 Hz, 2H), 7.38 (s, 1H), 6.96 (d, J = 8.0 Hz, 2H), 6.38 (s, 1H), 4.28 (brs, 2H), 3.95 (s, 3H), 3.88 (s, 3H), 3.86 (s, 3H); 13 C NMR (101 MHz, CDCl 3 ) δ: 55.6, 55.9, 57.2, 98.4, 98.9, 114.1, 124.1, 133.8, 141.3, 141.9, 147.9, 153.9, 160.8; IR (ATR, neat) ν = 3431, 3344, 3222.0, 3004.0, 2924 , 2836 , 1633 , 1578 , 1301 , 1035 According to the general procedure A and starting from 4-prop-2-ynyloxy-phenylamine 1d (57 mg, 0.39 mmol), after purification by flash column chromatography (PE/EtOAc: 6/4), the diazenyl aniline product 2d was isolated as a red solid (56 mg, 46%). R f = 0.33 (PE/EtOAc: 6/4); Mp = 163°C; 1 H NMR (250 MHz, CDCl 3 ) δ: 7.84 (d, J = 10.0 Hz, 2H), 7.38 (s, 1H), 7.03(d, J = 10.0 Hz, 2H), 6.39 (s, S5 1H), 4.74 (d, J = 2.5 Hz, 2H), 4.29 (brs, 2H), 3.96 (s, 3H), 3.89 (s, 3H), 2.54 (t, J = 2.5 Hz, 1H); 13 C NMR (101 MHz, CDCl 3 ) δ: 56. 0, 56.2, 57.2, 75.9, 78.5, 98.4, 98.9, 115.2, 124.1, 133.9, 141.5, 142.0, 148.5, 154.1, 158.7; IR (ATR, neat) ν= 3453, 3338, 3285, 2920 , 2128 , 1623 , 1508 , 1299 , 1018 
d. (E)-4-((4-(prop-2-ynyloxy)phenyl)diazenyl)aniline (2d)
H
General procedure (B) for bromoacetamide formation (3a-d)
The starting amine 2a-d (1.00 equiv.) was dissolved in dry THF (20 mL), and the solution was placed in an ice-water bath, then pyridine (1.25 equiv.) was introduced. A solution of bromoacetic bromide (1.00 equiv.) in dry THF (3 mL) was prepared and introduced dropwise to the mixture. The reaction was vigorous stirred for 30 min at 0 °C. After TLC control, the reaction was hydrolyzed at 0°C. The residue was extracted with ethyl acetate, washed twice with water and dried over magnesium sulfate. After filtration, the residue was concentrated and purified by flash column chromatography on SiO 2 . On the basis of the general procedure B and starting from the amine 2a (200 mg, 0.60 mmol), the amide 3a was isolated after purification by flash column chromatography (PE/EtOAc: 6/4) as a dark orange solid (258 mg, 95% 29.7, 56.4, 57.1, 98.0, 104.3, 124.4, 124.8, 131.6, 132.3, 137.2, 142.8, 151.9, 153.2, 163.7 On the basis of the general procedure B and starting from the amine 2b (100 mg, 0.34 mmol), the amide 3b was isolated after purification by flash column chromatography (PE/EtOAc: 6/4) as a dark orange solid (133 mg, 94% 29.7, 56.4, 57.1, 98.0, 104.3, 124.2, 129.4, 131.5, 136.4, 137.2, 142.8, 151.6, 153.1, 163.7 According to the general procedure B and starting from the amine 2c (150 mg, 0.52 mmol), the product 3c was isolated after purification by flash column chromatography (PE/EtOAc: 7/3) as a red 29.7, 55.6, 56.4, 57.1, 98.2, 104.5, 114.2, 124.8, 130.3, 137.5, 142.8, 147.5, 152.2, 161.8, 163.7 According to the general procedure B and starting from the amine 2d (30 mg, 0.10 mmol), the amide 3d was isolated after purification by flash column chromatography (PE/EtOAc: 4/6) as a dark orange solid (33 mg, 81% 29.7, 56.1, 56.4, 57.1, 76.0, 78.2, 98.1, 104.4, 115.2, 124.6, 130.6, 137.5, 142.7, 148.0, 152.4, 159.6, 163.6; IR (ATR, neat) ν= 3369, 3237, 2924 , 2125 , 1689 , 1596 , 1480 , 1204 , 1030 
General procedure (C) for the synthesis of DO3A derivatives (4a-d)
A solution of triester cyclen 1 (1.00 equiv.) and Na 2 CO 3 (3.00 equiv.) in anhydrous THF (5 mL) was stirred for 30 min. at room temperature under argon. A solution of bromoacetamide 3a-d (1.00 equiv.) in anhydrous THF (2 mL) was added dropwise, and the reaction was refluxed for 8h. After cooling and filtration, the solid residue was washed with dichloromethane and methanol. The filtrate was concentrated and purified by column chromatography on SiO 2 . According to the general procedure C, the product 4a was isolated after purification by column chromatography (CH 27.9, 27.9, 55.5, 56.1, 56.2, 57.5, 57.6, 81.9, 82.0, 97.8, 106.9, 124.3, 124.6, 132.2, 132.3, 137.5, 143.9, 151.9, 153.0, 171.5, 172.7 According to the general procedure C, the product 4b was isolated after purification by column chromatography (CH 2 Cl 2 /MeOH: 95/5) as a red solid (95 mg, 98% 27.9, 55.5, 56.1, 56.2, 57.5, 81.9, 97.8, 106.8, 124.0, 129.3, 132.3, 136.1, 137.4, 143.9, 151.5, 153.0, 171.5, 172.7; IR (ATR, neat): ν = 3384, 2974 , 2828 , 1724 , 1527 , 1223 , 1105 , 1008 According to the general procedure C, the product 4c was isolated after purification by column chromatography (PE/EtOAc: 4/6) as a red-orange solid (219 mg, 57% 55.6, 55.6, 56.2, 57.6, 57.8, 82.0, 98.1, 107.1, 114.2, 124.7, 130.9, 137.9, 143.7, 147.5, 152.2, 161.8, 171.1, 172.8 According to the general procedure C, the product 4d was isolated after purification by column chromatography (CH 2 Cl 2 /MeOH: 9/1) as a red solid (63 mg, 95% 27.8, 27.9, 55.4, 56.0, 56.0, 56.1, 57.4, 57.7, 75.9, 78.0, 81.92, 81.9, 97.9, 107.1, 115.1, 124.5, 131.1, 137.7, 143.7, 147.9, 152.2, 159.4, 171.1, 172.7 .; IR (ATR, neat) ν = 3360, 3291, 2974, 2834, 2107, 1723, 1673, 1593, 1250, 1023, 840 
General procedure (D) for deprotecting tert-butyl esters: (5a-d)
A solution of 2% of triisopropylsilane in trifluoroacetic acid (2mL) was added to the starting ester 4a-d (0.05 mmol). The deprotection reaction was carried out at room temperature for 60 min. Volatile compounds were evaporated and the product was precipitated with diethyl ether (5mL). After filtration through a Millipore filter and washings with diethyl ether, the residue was dried under vacuum to provide 5a-d as red gum. According to the general procedure D, the deprotected product 5a (38 mg) was isolated in quantitative yield as a red gum. 211.3, 183.8, 156.3, 133.4, 133.4, 128.8, 125.4, 125.3, 73.9, 57.8, 56.6, 28.4, 28.3, 18.9 ; IR (ATR, neat): ν = 3375, 2974, 2852, 1679, 1593, 1534, 1454, 1394, 1125, 832, 720 28.3, 44.9, 56.9, 57.8, 58.4, 77.2, 99.3, 110.1, 116.3, 116.4, 119.3, 125.6, 149.0, 152.9, 162.7, 162.8, 163.1, 210.6; IR (ATR, neat): ν = 3387, 3285, 2923 , 2848 , 1674 , 1591 , 1236 , 1017 
a. (E)-2,2',2''-(10-(2-(4-((4-bromophenyl)diazenyl)-2,5-dimethoxyphenylamino)-2-oxoethyl)-
General procedure of complexation of triacids with lanthanide salts
To a solution of the triacid 5a-d (1.00 equiv.) in methanol (2 mL), Ln(OTf) 3 (1.00 equiv.) was added as one single portion. The reaction was carried out for 24 h at 50 °C. Residues were taken up into methanol. Then the volume of solvent was reduced under vacuum and a product was precipitated with diethyl ether (5mL). After filtration through a Millipore filter and washing with diethyl ether, the residue was dried under vacuum to provide complexes as red-violet gums. 
a) H-Asp(O-Wang resin)-OAll (S1)
High loading Wang resin (750 mg, 1.2 mmol/g, 0.9 mmol) was introduced in a polypropylene syringe fitted with a polypropylene frit and was subsequently swollen in anhydrous DMF (10 mL for 30 min) under a dry argon atmosphere. The solvent was then removed under argon and the swelling step was repeated once for 5 min. The syringe was then fitted with a polypropylene plunger and a Teflon stopcock. Fmoc-Asp-OAll (712 mg, 2.0 equiv.) was dissolved in 10 mL anhydrous CH 2 Cl 2 under argon and the resulting solution was cooled in an ice bath. DCC (185 mg, 1.0 equiv.) was added and the mixture stirred for 20 min at 0°C. The white dicyclohexylurea precipitate was filtered off under argon, via a cannula and through a sintered glass funnel. Solvents were removed in vacuo and the white residue was dissolved in 6 mL anhydrous DMF. This solution was transferred under argon to the resin by suction, followed by DMAP (7 mg, 0.1 equiv.) dissolved in 1 mL anhydrous DMF. The resulting suspension was stirred by rotation for 4 h at RT. The resin was extensively washed with DMF then CH 2 Cl 2 . Capping of the residual hydroxyl groups from the Wang resin was achieved by treatment with Ac 2 O (2.5 mL, 29 equiv.) and N-methyl-morpholine (2.5 mL, 30 equiv.) in CH 2 Cl 2 (10 mL) for 2 h at RT, followed by extensive washes with CH 2 Cl 2 then DMF. The Fmoc group was deprotected using 20% piperidine in DMF (3 × 3 min), followed by extensive washes with DMF. The esterification yield (87%, 0.783 mmol) was determined by UV titration of the fluorenylmethylpiperidine co-product ( = 7800 L.mol -1 .cm -1 at  = 301 nm).
b) H-Gly-Asp(O-Wang resin)-OAll·TFA (S2)
In a syringe fitted with a frit, H-Asp(O-Wang resin)-OAll (S1, 0.783 mmol) was swollen in DMF (10 mL, 2 × 1 min). The solvent was drained off thoroughly and the syringe was fitted with a plunger and a Teflon stopcock. Fmoc-Gly-OH (477 mg, 2.05 equiv.) dissolved in 3 mL DMF was transferred to the resin by suction, followed by HATU (595 mg, 2.0 equiv.) in 2 mL DMF then DIEA (546 µL, 4.0 equiv.). The resulting suspension was stirred by rotation for 1h at RT, followed by extensive washes with DMF then CH 2 Cl 2 . A Kaiser test 2 performed on a few beads of resin indicated the absence of any unreacted amine. At this stage, we anticipated a side reaction if a standard protocol would be used for the Fmoc deprotection, e.g. the formation of the diketopiperazine (DKP) cyclo(Gly-Asp(Wang resin) (S2') arising from the attack of the liberated amine on the allyl ester. Related DKP formation is indeed a common problem encountered during and after treatment with piperidine of Fmoc-Xaa-Yaa esters of Wang or related resin, when Xaa and/or Yaa are Gly or Pro residues. 3 Confirming this, severe yield loss were observed when using a standard Fmoc deprotection protocol (3 × 3 min treatments with 20% piperidine in DMF) followed by storage of the resulting peptidyl resin at RT for a few hours. This could be judged by subsequent coupling of Fmoc-Arg(Pbf)-OH followed by Fmoc deprotection and UV titration of the fluorenylmethylpiperidine co-product. In consequence, a slightly modified Fmoc deprotection protocol was optimized to solve this issue. The resin was treated with 30% piperidine DMF (10 mL, 6 × 10 s) then immediately with CH 2 Cl 2 (10 s flow wash) then immediately with 0.5% TFA in CH 2 Cl 2 (10 mL, 4 × 2 s) in order to switch off the nucleophilicity of the terminal amine by protonation. The resin was then immediately extensively washed with CH 2 Cl 2 . UV titration of the fluorenylmethylpiperidine co-product confirmed a quantitative Fmoc deprotection.
c) Fmoc-D-Phe-Anl-Arg(Pbf)-Gly-Asp(O-Wang resin)-OAll (S3)
In a syringe fitted with a frit, H-Gly-Asp(O-Wang resin)-OAll, TFA (assumed 0.783 mmol) was swollen in DMF (2 × 10 mL for 1 min). The solvent was drained off thoroughly and the syringe was fitted with a plunger and a Teflon stopcock. Fmoc-Arg(Pbf)-OH (1.04 g, 2.05 equiv.) dissolved in 3 mL DMF was transferred to the resin by suction, followed by HATU (595 mg, 2.0 equiv.) in 2 mL DMF then DIEA (546 µL, 4.0 equiv.). The resulting suspension was stirred by rotation for 1 h at RT, followed by extensive washes with DMF then CH 2 Cl 2 . A Kaiser test performed on a few beads of resin indicated the absence of any unreacted amine. The Fmoc group was deprotected using 20% piperidine in DMF (3 × 3 min), followed by extensive washes with DMF. UV titration of the fluorenylmethylpiperidine co-product (0.744 mmol) allowed to indirectly quantifying the amount of diketopiperazine formed during our specific Fmoc deprotection protocol and the subsequent coupling (5%). Fmoc--azido-norleucine-OH (Fmoc-Anl-OH, 633 mg) then Fmoc-D-Phe-OH (622 mg) were then coupled using the same conditions as for Fmoc-Arg(Pbf)-OH followed by a standard Fmoc deprotection protocol, to give the peptidyl resin Fmoc-D-Phe-Anl-Arg(Pbf)-Gly-Asp(O-Wang resin)-OAll (S3). An aliquot (~ 0.5%) of the resin was treated with 20% piperidine in DMF (3 × 3min) then cleaved by treatment with a 1 mL of a TFA/phenol/H 2 O/iPr 3 SiH cocktail (87.5:5:5:2.5) for 2 h, after Fmoc protection under standard conditions. After filtration of the resin, the solution was poured into ice-cooled Et 2 O (10 mL). The white precipitate was isolated by centrifugation, then washed twice with Et 2 O (10 mL, followed by centrifugation) and dried under reduced pressure to give a white solid. HPLC analysis indicated an excellent purity of the crude resulting pentapeptide H-D-Phe-Anl-ArgGly-Asp-OAll (S3').
2. E. Kaiser, R. L. Colescott, C. D. Bossinger, P. I. Cook, Anal. Biochem., 1970, 34, 595. 3. E. Pedroso, A. Grandas, F. X. C. de las Heras, E. Giralt, Tetrahedron Lett., 1986, 27, 743. Under an argon atmosphere, in a syringe fitted with a frit, a plunger and a Teflon stopcock, Fmoc-DPhe-Anl-Arg(Pbf)-Gly-Asp(O-Wang resin)-OAll (S3, assumed 0.740 mmol) was swollen in dry CH 2 Cl 2 (10 mL, 2 × 1 min). The solvent was drained off then tetrakis(triphenylphosphine)palladium(0) (427 mg, 0.50 equiv.) dissolved in anhydrous CH 2 Cl 2 (15 mL) was transferred to the resin by suction, immediately followed by phenylsilane (0.91 mL, 10.0 equiv.). The resulting suspension was stirred by rotation for 2h at RT followed by extensive washes with CH 2 Cl 2 then DMF. The dark-coloured peptidyl resin was subsequently washed with a 0.1 M sodium diethyldithiocarbamate solution in NMP then a 1 M pyridinium chloride solution in CH 2 Cl 2 /MeOH (95:5), these two steps being repeated until the resin recovered its initial yellowish colour-(ca 3-4 times). An aliquot (~ 0.5%) of the resin was then cleaved using the same protocol as for S3. HPLC analysis of the resulting white solid indicated that the allyl ester deprotection was complete, as no trace of S3' could be detected. (1) 
S15
In a polypropylene syringe fitted with a polypropylene frit, Fmoc-D-Phe-Anl-Arg(Pbf)-Gly-Asp(OWang resin)-OH (S4, assumed 0.736 mmol) was swollen in DMF (10 mL, 2 × 1 min). The Fmoc group was deprotected using 20% piperidine in DMF (3 × 3 min), followed by extensive washes with DMF then 0.5% TFA in -CH 2 CL 2 (100 mL, 9.15 equiv., flow wash) then immediately with CH 2 Cl 2 . The resin was swollen in DMF (2 × 10 mL for 1 min). The solvent was drained off thoroughly and the syringe was fitted with a plunger and a Teflon stopcock. PyAOP (3.84 g, 10 equiv.) dissolved in 10 mL DMF was transferred to the resin by suction, followed by DIEA (2.56 mL, 20 equiv.). The resulting suspension was stirred by rotation for 1.5 h at RT, followed by extensive washes with DMF then CH 2 Cl 2 . A Kaiser test performed on a few beads of resin indicated the absence of any unreacted amine.
The resin was then cleaved by treatment with a TFA/phenol/H 2 O/TIS mixture (87.5:5:5:2.5, 15 mL) for 2h. The resin was filtered off then washed with TFA (3 x 3 mL). The combined supernatants were poured into ice-cold Et 2 O (300 mL). The white precipitate was isolated by filtration over a sintered glass funnel, then washed with Et 2 O (3 × 100 mL) and dried under reduced pressure to give a white solid. The crude mixture was purified by RP-HPLC to give the desired azido-cyclopeptide 6 as a white powder (288 mg, 43 % over 13 steps, based on initial resin loading, and taking into account a trifluoroacetate counter ion but not any eventual residual water). HPLC trace of the pure product 6 (Chromolith column HR RP-18e, 150 Å, 10 × 4.6 mm, 3 mL/min flow rate, gradient 5 to 50% B over 5 min):
(1) Solution A: Under an argon atmosphere, a solution of complex 5d-Yb (15.0 mg, 17.90 µmol, 1.00 equiv.) in H 2 O (500 µL) was mixed with a solution of azido-cyclopeptide 6 (16.9 mg, 26.85 µmol, 1.50 equiv.) in HEPES buffer (500 µL, 400 mM, pH=7.5); this solution A was diluted with 500 µL H 2 O, followed by one drop of DMF to solubilise the peptide. Separately, in a 1.5 mL centrifuge tube, a catalyst solution B was prepared: ligand THPTA (tris(3-hydroxypropyltriazolylmethyl)amine) (41.27 mg, 94.98 µmol, 5.30 equiv.) and aminoguanidine (29.7 mg, 268.5 µmol, 15.0 equiv.) were dissolved in 500 µL H 2 O. A solution of CuSO 4 ·5H 2 O (17.88 mg, 71.6 µmol, 4 equiv.) in 200 µL H 2 O was then added (apparition of an intensive blue colour), followed by a solution of sodium ascorbate (27.94 mg, 143.2 µmol, 8 equiv.) in 250 µL H 2 O (the solution became slightly yellow). The mixture B was immediately added to solution A. The reaction (A+B) was vigorously stirred for 30 min at RT, followed by analytical HPLC to confirm the completion of the cycloaddition reaction, then quenched by addition of 1 mL of a 5% aqueous TFA solution. The content of the flask was centrifuged to remove the precipitate and the supernatant was purified by semi-preparative HPLC (gradient 22/78 to 37/63 A/B, for 30 min., t R = 17.2 min.), leading to the expected complex 7-Yb (11.5 mg, 40%, taking into account one trifluoroacetate counteranion but no eventual water content The reaction (A+B) was vigorously stirred for 30 minutes at RT, followed by analytical HPLC then quenched by addition of 1mL of a 5% aqueous TFA solution. The content of the flask was centrifuged to remove the precipitate and the supernatant was purified by semi-preparative HPLC (gradient CH 3 CN/H 2 O (+0.1% TFA) 22/78 to 37/63, 3mL/min., 30 min., t R =17.2 min.) leading to the expected complex 7-Nd (40% yield, taking into account one trifluoroacetate counter anion but no eventual water content The reaction (A+B) was vigorously stirred for 30 minutes at RT, followed by analytical HPLC then quenched by addition of 1mL of an aqueous 5% TFA. The content of the flask was centrifuged to remove the precipitate and the supernatant was purified by semi-preparative HPLC (Nucleosil, RP-C18, gradient CH 3 CN/H 2 O (+0.1% TFA) 22/78 to 37/63, 3mL/min., 30 min., t R = 15.8 min.) leading to the expected complex 7-Gd (36% yield, taking into account one trifluoroacetate counteranion but
Photophysical measurements
All photophysical measurements were performed on freshly prepared solutions in Milli-Q water or D 2 O (0.2 -1 mM). Phosphorescence spectra of the 7-Gd complex were recorded in aqueous solution with addition of 10 % of glycerol. Absorption spectra were measured on a UVIKON XL spectrophotometer from Secomam using quartz Suprasil cells (Hellma® 115F-QS, bandpass 0.2 cm). For collecting luminescence data samples were placed into 2.4 mm i.d. quartz capillaries or quartz Suprasil cells. Emission and excitation spectra were measured on a custom-built Horiba-Jobin-Yvon Fluorolog 3 spectrofluorimeter equipped with a visible photomultiplier tube operating in photon counting mode (Hamamatsu R928P) and a NIR detector, either a solid state Electro-Optical Systems, Inc DSS-IGA020L InGaAs detector cooled to 77 K or a Hamamatsu H10330-45 photomultiplier tube operating in photon-counting mode. All spectra were corrected for the instrumental functions. Luminescence lifetimes were determined under excitation at 355 nm provided by a YG 980 Quantel Nd:YAG laser while the emission signal was detected in the near-infrared (950-1450 nm, a photoncounting unit H10330-45 from Hamamatsu) ranges. The output signal from the detector was then fed to a Tektronix TDS 754C 500MHz bandpass digital oscilloscope and then transferred to a PC for treatment with Origin 8®. Lifetimes are averages of at least three independent measurements. Quantum yields were determined with the fluorimeter described above according to an absolute method using an integration sphere (GMP SA, Renens, Switzerland). Each sample was measured several times under slightly different experimental conditions. Estimated experimental error for quantum yields determination is 10 %. 
